Vera Therapeutics (VERA) Cash & Current Investments (2020 - 2026)

Vera Therapeutics has reported Cash & Current Investments for 7 years, with the latest figure at $596.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 1.17% year-over-year to $596.8 million; the trailing twelve-month figure through Mar 2026 stood at $596.8 million (up 1.17% YoY), and the FY2025 full-year result was $714.6 million, up 11.51% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $596.8 million, down from $714.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $714.6 million in Q4 2025, with the low at $114.4 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $349.9 million across 5 years, with a median of $353.3 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Current Investments jumped 298.75% — and 2026, when it increased 1.17%.
• Vera Therapeutics' Cash & Current Investments stood at $114.7 million in 2022, then soared by 40.18% to $160.7 million in 2023, then jumped by 298.75% to $640.9 million in 2024, then increased by 11.51% to $714.6 million in 2025, then slipped by 16.49% to $596.8 million in 2026.
• The last three Cash & Current Investments figures came in at $596.8 million (Q1 2026), $714.6 million (Q4 2025), and $497.4 million (Q3 2025), per Business Quant data.